Physician profile
Eric J Freeman
NPI 1184626947
$793.74
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $107 · 2021: $233.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $232.61 | 2021 | |
| Glaxosmithkline, LLC. | $180.49 | 2019-2020 | |
| Genentech USA, INC. | $112.72 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $56.33 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $54.31 | 2019-2020 | |
| Grifols USA, LLC | $45.72 | 2019-2020 | |
| Resmed Corp | $36.67 | 2019-2020 | |
| Insmed, INC. | $24.17 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.36 | 2019 | |
| Astellas Pharma US INC | $15.36 | 2019 | |
| Circassia INC. | $13.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.